-rheumatic drug
Previous studies have shown that INF has the characteristics of       disease-modifying anti-rheumatic drug (DMARD) in that it has a component of       slow-acting effect in treatment of rheumatoid arthritis (RA), in which abnormal B       cell functions are considered to be involved.
Previous studies have shown that INF has the characteristics of       disease-modifying anti @SUBJECT$  (DMARD) in that it has a component of       slow-acting effect in  @PREDICAT$  of  @OBJECT$  (RA), in which abnormal B       cell functions are considered to be involved.